Levator ani syndrome (LAS) is a chronic pelvic pain disorder characterized by recurrent episodes of pain in the rectum or lower pelvis, often exacerbated by sitting or pressure on the pelvic floor muscles. Despite being a relatively common condition, LAS is frequently underrecognized and can significantly impair patients’ quality of life. This review aims to provide a comprehensive overview of levator ani syndrome, encompassing its etiology, pathophysiology, clinical manifestations, diagnostic approaches, and management strategies.

Etiology and Pathophysiology: The etiology of levator ani syndrome remains incompletely understood, with multifactorial mechanisms likely contributing to its development. Proposed etiological factors include pelvic floor muscle dysfunction, psychological stressors, visceral hypersensitivity, and central sensitization. Dysfunction of the levator ani muscles, characterized by hypertonicity, spasms, or myofascial trigger points, is thought to play a central role in the pathophysiology of LAS. Chronic pelvic floor muscle tension may lead to ischemia, inflammation, and sensitization of nociceptive pathways, perpetuating the cycle of pain and discomfort.

Clinical Features: Levator ani syndrome typically presents with chronic, dull, or aching pain localized to the rectum, perineum, or coccyx, often described as a pressure or discomfort sensation. Symptoms may be intermittent or persistent and may worsen with prolonged sitting, defecation, or sexual activity. Patients may also report urinary symptoms, including frequency, urgency, or hesitancy, and psychological comorbidities such as anxiety or depression are common. The absence of organic pathology on physical examination and diagnostic studies distinguishes LAS from other pelvic pain disorders.

Diagnostic Evaluation: The diagnosis of levator ani syndrome is primarily clinical and relies on a thorough history and physical examination. Digital rectal examination may reveal tenderness or hypertonicity of the levator ani muscles, although findings may be variable and nonspecific. Diagnostic criteria for LAS include chronic or recurrent pelvic pain lasting at least three months, absence of structural abnormalities on imaging studies, and exclusion of other organic causes of pelvic pain. Additional diagnostic modalities, such as electromyography (EMG) or dynamic MRI, may aid in confirming pelvic floor muscle dysfunction and guiding treatment decisions.

Management Strategies: The management of levator ani syndrome is multimodal and individualized, focusing on symptom relief, functional improvement, and addressing underlying contributing factors. Conservative treatment modalities include pelvic floor physical therapy, biofeedback, relaxation techniques, and dietary modifications to alleviate symptoms and reduce pelvic floor muscle tension. Pharmacotherapy, including muscle relaxants, tricyclic antidepressants, or neuropathic pain medications, may be beneficial in some cases. For refractory symptoms, invasive interventions such as trigger point injections, nerve blocks, or botulinum toxin injections into the levator ani muscles may be considered, although evidence supporting their efficacy is limited.

Conclusion: Levator ani syndrome is a chronic pelvic pain disorder characterized by recurrent episodes of rectal or pelvic discomfort, often exacerbated by pelvic floor muscle dysfunction. Despite its significant impact on patients’ quality of life, LAS remains underrecognized and challenging to manage. A multidisciplinary approach, incorporating conservative therapies, pharmacotherapy, and interventional strategies, is essential for optimizing outcomes and improving the quality of life for individuals affected by levator ani syndrome. Continued research efforts aimed at elucidating the underlying pathophysiology and identifying effective treatment modalities are warranted to address the unmet needs of patients with this complex pelvic pain disorder.